QNRX Quoin Pharmaceuticals Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1671502
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-42.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-142.5%
ROA-95.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets17.4%
Debt / equity0.00x
Current ratio7.20x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.66M | $3.63M | $3.43M | $3.10M | $2.28M | $2.05M | $2.37M | $1.07M |
| SG&A expense | $2.27M | $1.85M | $1.70M | $1.42M | $1.74M | $1.74M | $1.58M | $1.33M |
| Net income | -$4.87M | -$5.37M | -$5.00M | -$4.35M | -$3.95M | -$3.70M | -$3.81M | -$2.31M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $10.10M | $3.85M | $3.12M | $3.82M | $1.83M | $1.67M | $3.82M | $3.62M |
| Short-term investments | $23.08M | $6.95M | $10.92M | $14.93M | — | — | — | $10.43M |
| Current assets | $34.40M | $11.64M | $15.33M | $20.01M | $6.02M | $8.48M | $12.50M | $14.93M |
| Intangibles | $308,334 | $333,334 | $358,334 | $383,334 | $408,334 | $433,334 | $458,334 | $483,334 |
| Total assets | $34.75M | $11.97M | $15.69M | $20.39M | $6.42M | $8.91M | $12.96M | $15.71M |
| Current liabilities | $4.78M | $6.61M | $5.35M | $5.55M | $5.76M | $4.34M | $4.86M | $4.18M |
| Total liabilities | $6.05M | $8.04M | $6.92M | $7.27M | $7.64M | $6.36M | $7.03M | $6.50M |
| Shareholders' equity | $28.70M | $3.93M | $8.77M | $13.12M | -$1.21M | $2.55M | $5.93M | $9.20M |
| Shares outstanding | 168.15M | 70.29M | 68.64M | 52.44M | 20.59M | 20.59M | 20.59M | 8.95M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.77M | -$3.14M | -$4.87M | -$5.04M | -$2.23M | -$3.69M | -$2.59M | -$2.24M |
| Investing cash flow | -$16.09M | $4.02M | $4.12M | -$11.27M | $2.54M | $1.68M | $2.77M | -$3.18M |
| Financing cash flow | $28.11M | -$151,947 | $55,982 | $18.29M | -$150,000 | -$150,000 | $22,958 | $5.92M |
| Stock-based compensation | $484,000 | $532,000 | $444,525 | $283,205 | $182,000 | $321,000 | $360,357 | $326,332 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.